AMPH Q1 2024 Earnings — Amphastar Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

AMPHAmphastar Pharmaceuticals, Inc.

$894M

Q1 2024 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$172M+22.7% YoY

Gross Profit

$87M50.8% margin

Operating Income

$48M27.9% margin

Net Income

$43M25.1% margin

EPS (Diluted)

$0.81

QoQ Revenue Growth

-3.5%

Cash Flow

Operating Cash Flow

$55M

Free Cash Flow

$46M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$1.6B

Total Liabilities

$902M

Stockholders' Equity

$672M

Cash & Equivalents

$201M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$172M	$140M	+22.7%
Gross Profit	$87M	$74M	+18.2%
Operating Income	$48M	$33M	+43.6%
Net Income	$43M	$26M	+65.9%

Revenue Segments

Research and development services

$400,000100%

Geographic Segments

UNITED STATES

$170M99%

FRANCE

$2M1%

CHINA

$403,0000%